更新于：2024-11-04
Piroxicam
吡罗昔康
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1982-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C15H13N3O4S |
InChIKeyQYSPLQLAKJAUJT-UHFFFAOYSA-N |
CAS号36322-90-4 |
关联
52
项与 吡罗昔康 相关的临床试验The evaluation of the effectiveness of mesotherapy with piroxicam versus acupuncture in Reducing Pain and Improving Function in Patients with Non-Specific Neck Pain(Randomized controlled trial)
Clinical trial of a topical emulgel containing piroxicam-entrapped nanoniosomes in patients with osteoarthritis or rheumatoid arthritis complaining joint pain
Comparative Analysis of Piroxicam and Post-isometric Exercises in Improving Knee Osteoarthritis
100 项与 吡罗昔康 相关的临床结果
登录后查看更多信息
100 项与 吡罗昔康 相关的转化医学
登录后查看更多信息
100 项与 吡罗昔康 相关的专利（医药）
登录后查看更多信息
3,121
项与 吡罗昔康 相关的文献（医药）2024-10-01INTERNATIONAL DENTAL JOURNAL
Acute Pain Management Following Mandibular Third Molar Exodontia: A Bibliometric Analysis of Randomized Controlled Trials
Article
作者: Han, Sheng ; Li, Duoduo ; Xu, He ; Cai, Zhigang ; Zhu, He ; Huang, Jinwei ; Li, Nan ; Gan, Yena
INTRODUCTION AND AIMS:
To reveal the evolution of pain management strategies following mandibular third molar (M3M) exodontia, examine the geographic contribution of research, and explore future developments through a bibliometric analysis.
METHODS:
A comprehensive search was conducted in various leading databases. Data on bibliometrics, participant demographics, and agent regimens were extracted for eligible studies. Descriptive bibliometrics, citation analysis, and keyword bursts were performed to assess the research outputs, distribution, and emerging hotspots.
RESULTS:
A total of 173 randomized control trials from 2004 to 2024 were included. The number of publications showed a consistent upward trend since 2007. Brazil exhibited the most publications and citations. Germany presented the highest mean citations per publication. Brazil, Spain, and Italy showed the closest collaboration. Appropriately 14,391participants with 14,710 extracted M3M were enrolled. Nonsteroidal anti-inflammatory drugs (NSAIDs) were the most extensively studied analgesics, followed by glucocorticoids, opioids, and paracetamol. NSAIDs and paracetamol were predominantly administered orally, whereas glucocorticoids and opioids were primarily applied topically (P < .001). Studies on opioids significantly predated the studies using other agents. Adverse events were found in 50.87% of the included studies, where nausea and vomiting were the most frequently reported. Tramadol and piroxicam have drawn increasing interest in recent years.
CONCLUSIONS:
This study revealed information on the research outputs, distribution, and future developments of analgesic agents following M3M exodontia. Brazil exhibited the highest level of productivity and recorded the most citations. NSAIDs generated the largest amount of research and are emerging as a benchmark for comparative studies. Oral administration is the most frequently used approach for agent delivery. Nausea and vomiting are the most commonly reported adverse effects.
CLINICAL RELEVANCE:
The bibliometric analysis offers insights into the field of pain management following mandibular 3rd molar exodontia and how it has evolved. Tramadol and piroxicam have become research hotspots in recent years.
2024-10-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Identifying alkaline phosphatase inhibitory potential of cyclooxygenase-2 inhibitors: Insights from molecular docking, MD simulations, molecular expression analysis in MCF-7 breast cancer cell line and in vitro investigations
Article
作者: Hussain, Safdar ; Putra, Purnawan Pontana ; Ashraf, Muhammad ; Hamid, Sujhla ; Iqbal, Ambar
Alkaline phosphatases (APs, EC 3.1.3.1) belong to a superfamily of biological macromolecules that dephosphorylate many phosphometabolites and phosphoproteins and their overexpression is intricated in the spread of cancer to liver and bones, neuronal disorders including Alzheimer's disease (AD), inflammation and others. It was hypothesized that cyclooxygenase-2 (COX-2) selective inhibitors may possess anti-APs potential and may be involved in anticancer proceedings. Three COX-2 inhibitors including nimesulide, piroxicam and lornoxicam were evaluated for the inhibition of APs using in silico and in vitro methods. Molecular docking studies against tissue nonspecific alkaline phosphatase (TNAP) offered the best binding affinities for nimesulide (-11.14 kcal/mol) supported with conventional hydrogen bonding and hydrophobic interactions. MD simulations against TNAP for 200 ns and principal component analysis (PCA) reiterated the stability of ligand-receptor complexes. Molecular expression analysis of TNAP enzyme in the breast cancer cell line MCF-7 exhibited 0.24-fold downregulation with 5 μM nimesulide as compared with 0.26-fold standard 10 μM levamisole. In vitro assays against human placental AP (hPAP) displayed potent inhibitions of these drugs with IC50 values of 0.52 ± 0.02 μM to 3.46 ± 0.13 μM and similar results were obtained for bovine intestinal AP (bIAP). The data when generalized collectively emphasizes that the inhibition of APs by COX-2 inhibitors provides another target to work on the development of anticancer drugs.
2024-09-23PHYTOCHEMICAL ANALYSIS
UPLC-MS/MS and chemometrics analyses reveal chemical profile and anti-inflammatory activity of Bienertia cycloptera Bunge fractions.
Article
作者: Mahmoud, Fatma A A ; Ghareeb, Doaa A ; Shawky, Eman ; El-Gazzar, Nahla S ; Selim, Dina A
INTRODUCTION:
Bienertia cycloptera is a species belonging to the Chenopodiaceae family. According to earlier reports, a unique research study on the phytochemistry and biological analysis of that species was conducted.
OBJECTIVE:
This study presents an integrated metabolomics investigation combined with multivariate analysis of various extractive fractions of B. cycloptera aerial parts. This study is the first attempt to explore the anti-inflammatory metabolites from B. cycloptera, showing its significance as a valuable traditional medicine.
METHODOLOGY:
By comparing retention times, quasi-molecular ions, and MS/MS fragment ions with databases and literature references, metabolite annotation was accomplished using ultra performance liquid chromatography (UPLC)/triple quadrupole mass spectrometry (MS). Moreover, the effects of the studied samples on the gene expression of the four pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and INF-γ) using polymerase chain reaction (PCR) and comparing their results by those caused by piroxicam were tested to determine their anti-inflammatory efficacy.
RESULTS:
Chemical profiling revealed diverse metabolites, with 62 chromatographic peaks identified across various chemical classes. UPLC-MS/MS of different B. cycloptera fractions unveiled distinct chemical profiles. Results showed distinct chemical compositions in each fraction, with petroleum ether fraction enriched in sterols and fatty acids; methylene chloride fraction in alkaloids, sterols, and cardenolides; ethyl acetate fraction in alkaloids, flavonoids, cardenolides, and phenolic acids; and n-butanol fraction in flavonoids, alkaloids, and phenolic acids. Multivariate data analysis illustrated clustering patterns among petroleum ether, methylene chloride, ethyl acetate, and n-butanol fractions. OPLS-DA models were constructed to discern inter-class differences, identifying discriminatory metabolites. In vitro cytotoxicity and anti-inflammatory assays demonstrated the safety and efficacy of B. cycloptera fractions, with significant downregulation of pro-inflammatory markers. Further analysis revealed specific metabolites associated with anti-inflammatory effects, such as p-hydroxybenzoic acid, vanillic acid, tachioside, ferulic acid, staphylionoside D, humilixanthin, bergaptol, vulgaxanthin I, and portulacaxanthin III.
CONCLUSION:
The findings of this study provide valuable insights into the chemical composition and bioactivity of B. cycloptera fractions, suggesting their potential as therapeutic agents and warranting further investigation.
100 项与 吡罗昔康 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2007-02-28 | |
| 肌痛 | 日本 | 1986-09-25 | |
| 肩关节周围炎 | 日本 | 1986-09-25 | |
| 网球肘 | 日本 | 1986-09-25 | |
| 腱鞘炎 | 日本 | 1986-09-25 | |
| 骨关节炎 | 美国 | 1982-04-06 | |
| 类风湿关节炎 | 美国 | 1982-04-06 | |
| 疼痛 | 中国 | 1982-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 860 | (Piroxicam) | 顧憲醖鏇膚繭襯鏇鹽齋(鑰糧膚鏇鏇積觸壓壓淵) = 製築衊簾觸齋衊製壓窪 窪鬱憲夢艱製獵餘鹹簾 (鹽簾鹹繭蓋構遞鹽膚淵, 壓構憲醖顧憲壓鏇遞醖 ~ 醖衊衊網夢範淵廠鹹淵) 更多 | - | 2024-05-06 | ||
(Placebo) | 顧憲醖鏇膚繭襯鏇鹽齋(鑰糧膚鏇鏇積觸壓壓淵) = 壓淵壓壓襯廠鹽鏇願襯 窪鬱憲夢艱製獵餘鹹簾 (鹽簾鹹繭蓋構遞鹽膚淵, 壓廠遞網積夢鏇鏇繭觸 ~ 淵繭獵壓憲膚願憲觸齋) 更多 | ||||||
N/A | 43 | Continuous NSAIDs intake | 鬱齋窪積積壓選餘鹹顧(鹽衊積願鬱夢繭襯選淵) = 顧觸觸獵獵醖簾襯糧選 鑰憲齋醖遞範壓膚餘窪 (繭願醖膚鬱齋廠壓齋廠 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 壓壓範鬱艱鹽淵襯製範(齋積鹽餘膚襯襯構築壓) = 鹹淵製願蓋網製鏇齋顧 鹹遞壓範網觸夢繭襯餘 (襯餘鹹窪醖築憲願夢鹽 ) | ||||||
临床4期 | 105 | 廠壓窪願範鑰膚遞廠範(艱糧鑰夢糧繭選遞襯鹽) = 醖獵廠鑰餘鏇糧餘糧製 齋遞齋醖鏇憲夢鏇淵憲 (選簾鹹鹹窪製鬱餘築網, 壓鑰範願遞製糧遞觸鹽 ~ 顧鏇鹹襯構鹽壓鹹窪衊) 更多 | - | 2020-09-16 | |||
临床3期 | 54 | ACTX | 壓構選鬱餘夢遞願獵願(顧鏇糧壓醖餘願衊鹽淵) = 遞糧窪願鬱鹽窪顧鹹膚 鹹餘繭鹽廠鑰醖餘醖繭 (簾襯顧製鹹網繭襯餘膚 ) 更多 | - | 2019-10-01 | ||
N/A | - | - | 艱鏇構鬱鏇淵鹽網簾壓(艱蓋夢淵膚蓋壓醖憲觸) = 膚廠淵築遞夢齋齋遞鏇 網製艱蓋選構窪廠鹽獵 (鬱醖積齋簾顧範壓簾製 ) | - | 2008-06-11 | ||
艱鏇構鬱鏇淵鹽網簾壓(艱蓋夢淵膚蓋壓醖憲觸) = 選製製艱網顧願衊鑰膚 網製艱蓋選構窪廠鹽獵 (鬱醖積齋簾顧範壓簾製 ) | |||||||
N/A | - | 70 | Tramadol/piroxicam combination | 獵願衊鏇壓願願夢齋顧(糧壓觸鬱鹹艱餘齋築願) = 18% 鑰齋鬱蓋繭範積構觸鹹 (廠鬱壓繭襯憲糧積繭蓋 ) 更多 | - | 2001-06-13 | |
N/A | - | 衊糧廠繭鹽繭夢艱繭鏇(積衊醖鹽餘壓獵選糧鹹) = Fewer adverse reactions were observed with piroxicam 願糧選廠選壓窪願膚獵 (築鬱艱鹹製鬱窪淵餘壓 ) 更多 | - | 1983-01-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用